Medartis Holding AG
SIX:MED
Intrinsic Value
Medartis Holding AG operates as a medical device company. [ Read More ]
The intrinsic value of one
MED
stock under the Base Case scenario is
76.15
CHF.
Compared to the current market price of 80 CHF,
Medartis Holding AG
is
Overvalued by 5%.
Medartis Holding AG's market capitalization is 988.7m CHF.
MED stock price is 80 CHF.
MED stock (76.15 CHF) is 5% less than its price (80 CHF).
MED has upside potential of 32% compared to the average analyst price target.
Open Wall St Estimates
MED's ROIC (Return on Invested Capital) has increased in the last 3 years from 0% to 1%.
MED's ROE (Return on Equity) has increased in the last 3 years from 0% to 0%.
MED has positive Net Debt. This means that the company has more debt (36m CHF) than cash and short-term investments (25m CHF).
MED's Revenue has grown by 16% over the past 12 months.
MED's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
MED's Revenue is forecast to grow at a rate of 15% per year over the next 3 years.
MED's ROE (Return on Equity) for the past 12 months is very low and is equal to 0%.
MED has positive Free Cash Flow for the last twelve months.
MED has positive Operating Income for the last twelve months.
MED has positive Net Income for the last twelve months.
MED earns more than enough operating income (10m CHF) to safely cover interest payments on its debt (828k CHF).
MED's Revenue has been growing by 18% per year for the last 3 years.
MED has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
MED has a very low three-year average ROE (Return on Equity): 0%. The company is not efficient at transforming stockholders' equity into net income.
MED has positive Gross Profit for the last twelve months.
MED's short-term assets (141m CHF) exceed its short-term liabilties (46m CHF).
MED's D/E (Debt to Equity) is very low and is equal to 0.14.
MED's long-term assets (350m CHF) exceed its long-term liabilties (95m CHF).
MED's Altman Z-Score is very high and is equal to 8.56.
Valuation Backtest
Medartis Holding AG
Run backtest to discover the historical profit from buying and selling
MED
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Medartis Holding AG
Balance Sheet Decomposition
Medartis Holding AG
| Current Assets | 141.4m |
| Cash & Short-Term Investments | 25.2m |
| Receivables | 46.6m |
| Other Current Assets | 69.6m |
| Non-Current Assets | 208.1m |
| Long-Term Investments | 34.3m |
| PP&E | 80.1m |
| Intangibles | 64.7m |
| Other Non-Current Assets | 29.1m |
| Current Liabilities | 46m |
| Accounts Payable | 8.2m |
| Accrued Liabilities | 3.3m |
| Short-Term Debt | 462k |
| Other Current Liabilities | 33.9m |
| Non-Current Liabilities | 48.6m |
| Long-Term Debt | 35.4m |
| Other Non-Current Liabilities | 13.2m |
Earnings Waterfall
Medartis Holding AG
|
Revenue
|
212m
CHF
|
|
Cost of Revenue
|
-44.4m
CHF
|
|
Gross Profit
|
167.6m
CHF
|
|
Operating Expenses
|
-157.9m
CHF
|
|
Operating Income
|
9.7m
CHF
|
|
Other Expenses
|
-9.1m
CHF
|
|
Net Income
|
619k
CHF
|
Free Cash Flow Analysis
Medartis Holding AG
MED Profitability Score
Profitability Due Diligence
Medartis Holding AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Medartis Holding AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
MED Solvency Score
Solvency Due Diligence
Medartis Holding AG's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Medartis Holding AG's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MED Price Targets Summary
Medartis Holding AG
According to Wall Street analysts, the average 1-year price target for
MED
is 105.57 CHF
with a low forecast of 96.46 CHF and a high forecast of 115.5 CHF.
Shareholder Return
MED Price
Medartis Holding AG
| Average Annual Return | 38.03% |
| Standard Deviation of Annual Returns | 118.77% |
| Max Drawdown | -58% |
| Market Capitalization | 988.7m CHF |
| Shares Outstanding | 13 558 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Medartis Holding AG
Country
Industry
Market Cap
Dividend Yield
Description
Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.
Contact
IPO
Employees
Officers
The intrinsic value of one
MED
stock under the Base Case scenario is
76.15
CHF.
Compared to the current market price of 80 CHF,
Medartis Holding AG
is
Overvalued by 5%.
You don't have any saved screeners yet
